DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22

JENA, 5 August 2022

Carl Zeiss Meditec generated revenue of 1,332.9m in the first nine months of fiscal year 2021/22 (prior year: 1,198.2m), corresponding to an increase of 11.2% (adjusted for currency effects: +9.8%) compared with the same period of the prior year. Order intake increased at a much higher rate than revenue, rising 36.0% to 1,750.5m (prior year: 1,287.6m). Earnings before interest and taxes (EBIT) at 275.9m were only slightly below the previous year's level of 282.8m, which had still benefited considerably from lower operating costs during the COVID-19 pandemic. The EBIT margin was 20.7% (prior year: 23.6%). The adjusted EBIT margin was 21.2% (prior year: 23.9%). 

Dr. Markus Weber: In the last few months, the continuing tense global supply chain situation and the COVID-19 lockdown in Shanghai have presented us with major challenges, but our teams have once again managed to overcome them superbly. I am therefore highly satisfied with the very solid revenue growth and the even stronger order intake. Our markets and our portfolio are developing at a strong pace.

Contributions to growth from all strategic business units and regions

Revenue in the Ophthalmic Devices strategic business unit (SBU) increased by 11.2% in the first nine months of fiscal year 2021/22 (adjusted for currency effects: +10.0%) to 1,027.2m (prior year: 923.4m). Recurring revenue from consumables, implants and services once again contributed significantly to the growth. The equipment business continued to be impacted by supply chain bottlenecks. Orders received in the Ophthalmic Devices SBU increased disproportionately to revenue. Revenue in the Microsurgery SBU increased by 11.2% (adjusted for currency effects: +9.2%) to 305.7m (prior year: 274.8m).  Orders received in the Microsurgery SBU likewise increased at a much higher rate than revenue.

Revenue in the EMEA^[1]region increased by 5.3% (adjusted for currency effects: +6.5%) to 334.2m (prior year: 317.3m). Orders received in the core European markets exhibited a very positive trend.

In the APAC^[2]region, revenue increased to 668.3m, compared with 575.0m in the prior year (+16.2%; adjusted for currency effects: +16.2%[3]). The strongest contributions to growth came from China and India. The Japanese market also recorded growth.

https://www.zeiss.de/meditec-ag/investor-relations/finanzkalender/telefonkonferenzen.html

Contact for investors and press

Sebastian Frericks

Director of Group Finance & Investor Relations, Carl Zeiss Meditec AG

Phone: 03641 220-116

Email: investors.meditec@zeiss.com
 

www.zeiss.com/press

^[1] Europe, Middle East, Africa

^[2] Asia/Pacific region

^[3] In the APAC region, invoicing to distributors is largely done in euros.